MEK blockage has poor clinical outcome in KRAS-mutant (KRASMT) colorectal cancer cells, and siRNA-mediated knockdown of macrophage inhibitory factor (MIF) restored sensitivity to refametinib by decreasing STAT3 phosphorylation [38]. Here, STAT3 is linked to colorectal cancer.